论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Sun B, Zhang Y, Zhou L, Yin L, Li F, Li C, Xia J
Received 11 December 2018
Accepted for publication 19 February 2019
Published 11 April 2019 Volume 2019:12 Pages 2767—2776
DOI https://doi.org/10.2147/OTT.S197740
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Ms Aruna Narula
Peer reviewer comments 3
Editor who approved publication: Dr Sanjeev Srivastava
Background: It has
been reported that miRNA-125b is associated with carcinogenesis and development
of several different kinds of cancers. Nevertheless, there is no clarity
regarding the significance and mechanism of action of miR-125b in clinical
practice for cervical cancer (CC).
Materials and methods: In the
current investigation, the expression of miR-125b in cervical clinical
specimens and CC cell lines was analyzed via real-time quantitative PCR, and
the relationship of miR-125b with the chromatin-associated protein high
mobility group A (HMGA1) expression and clinicopathological parameters of CC
patients was explored.
Results: The
results indicated that miR-125b expression was remarkably upregulated in CC
cell lines as well as in the tissues of humans. miR-125b overexpression was
significantly related to a decrease in HMGA1 expression, progression-free
survival, overall survival, and prognosis as well. Besides, knockdown of
miR-125b inhibited proliferation and colony formation in SW756 and C4-1 cells,
where the 3'-UTR of HMGA1 mRNA was directly targeted. Moreover, PI3K/Akt
pathway was regulated by miR-125b through suppression of HMGA1.
Conclusion: These
findings illustrated that a new regulatory role of HMGA1 is involved in the
progression of CC. Our data demonstrated that miR-125b could play a critical
role in the carcinogenesis and progression of CC, revealing that miR-125b might
serve as a potential new target for treating CC.
Keywords: cervical
cancer, CC, miR-125b, high mobility group A, HMGA1, progression-free survival,
PFS, overall survival, OS, prognosis
